IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial

Reuters

Nov 25

IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial

IN8BIO Inc. has announced new clinical data from its investigator-sponsored Phase 1 trial of INB-200 and Company-sponsored Phase 2 trial of INB-400 for the treatment of newly diagnosed glioblastoma. The results were presented in poster and oral sessions at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting on November 21 and 22, 2025. Across both trials, 17 patients were treated with the Company's DeltEx DRI gamma-delta T cells, with 14 patients receiving repeated doses. These patients achieved a median progression-free survival of 13.0 months, compared to 6.6 months for 10 patients who received only the standard-of-care Stupp protocol. Median overall survival for patients treated with repeated DeltEx DRI doses has not yet been reached and was reported at 16.4+ months as of October 31, 2025, while the standard-of-care group had a median overall survival of 11.0 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-292057), on November 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2586496697"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586496697\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586496697?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 00:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586496697","market":"us","top_or_hot":-1,"title":"IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IN8BIO Inc. has announced new clinical data from its investigator-sponsored Phase 1 trial of INB-200 and Company-sponsored Phase 2 trial of INB-400 for the treatment of newly diagnosed glioblastoma. The results were presented in poster and oral sessions at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting on November 21 and 22, 2025. Across both trials, 17 patients were treated with the Company's DeltEx DRI gamma-delta T cells, with 14 patients receiving repeated doses. These patients achieved a median progression-free survival of 13.0 months, compared to 6.6 months for 10 patients who received only the standard-of-care Stupp protocol. Median overall survival for patients treated with repeated DeltEx DRI doses has not yet been reached and was reported at 16.4+ months as of October 31, 2025, while the standard-of-care group had a median overall survival of 11.0 months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-292057), on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-25 00:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IN8BIO Inc. has announced new clinical data from its investigator-sponsored Phase 1 trial of INB-200 and Company-sponsored Phase 2 trial of INB-400 for the treatment of newly diagnosed glioblastoma. The results were presented in poster and oral sessions at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting on November 21 and 22, 2025. Across both trials, 17 patients were treated with the Company's DeltEx DRI gamma-delta T cells, with 14 patients receiving repeated doses. These patients achieved a median progression-free survival of 13.0 months, compared to 6.6 months for 10 patients who received only the standard-of-care Stupp protocol. Median overall survival for patients treated with repeated DeltEx DRI doses has not yet been reached and was reported at 16.4+ months as of October 31, 2025, while the standard-of-care group had a median overall survival of 11.0 months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-292057), on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL2dt6fH:1","article_id":"2586496697","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586496697","pubTimestamp":1764001031,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IN8BIO Inc. has announced new clinical data from its investigator-sponsored Phase 1 trial of INB-200 and Company-sponsored Phase 2 trial of INB-400 for the treatment of newly diagnosed glioblastoma. The results were presented in poster and oral sessions at the 2025 Society for Neuro-Oncology  Annual Meeting on November 21 and 22, 2025. Across both trials, 17 patients were treated with the Company's DeltEx DRI gamma-delta T cells, with 14 patients receiving repeated doses. These patients achieved a median progression-free survival of 13.0 months, compared to 6.6 months for 10 patients who received only the standard-of-care Stupp protocol. Median overall survival for patients treated with repeated DeltEx DRI doses has not yet been reached and was reported at 16.4+ months as of October 31, 2025, while the standard-of-care group had a median overall survival of 11.0 months.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","INAB":"IN8bio, Inc.","BK4539":"次新股"},"translate_title":"IN8BIO报告DeltEx DRI细胞在胶质母细胞瘤试验中有希望的存活数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INAB":0.9},"content_text":"IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial\n    \n\n        IN8BIO Inc. has announced new clinical data from its investigator-sponsored Phase 1 trial of INB-200 and Company-sponsored Phase 2 trial of INB-400 for the treatment of newly diagnosed glioblastoma. The results were presented in poster and oral sessions at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting on November 21 and 22, 2025. Across both trials, 17 patients were treated with the Company's DeltEx DRI gamma-delta T cells, with 14 patients receiving repeated doses. These patients achieved a median progression-free survival of 13.0 months, compared to 6.6 months for 10 patients who received only the standard-of-care Stupp protocol. Median overall survival for patients treated with repeated DeltEx DRI doses has not yet been reached and was reported at 16.4+ months as of October 31, 2025, while the standard-of-care group had a median overall survival of 11.0 months.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-292057), on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}